[{"orgOrder":0,"company":"Curetis","sponsor":"BioVersys AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Curetis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curetis \/ BioVersys AG","highestDevelopmentStatusID":"6","companyTruncated":"Curetis \/ BioVersys AG"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ AMR Action Fund","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ AMR Action Fund"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GSK"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GIBF2","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ GIBF2","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GIBF2"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ Inapplicable"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioVersys AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVersys AG \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Rifabutin Pfizer Brand

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : BV100 a novel formulation of rifabutin, being investigated in adults with ventilator associated bacterial pneumonia suspected or confirmed to be due to Carbapenem Resistant Acinetobacter baumannii.

                          Product Name : BV100

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 16, 2024

                          Lead Product(s) : Rifabutin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The company will expand the clinical development of its lead asset BV100, a novel formulation of rifabutin being developed for hospital infections caused by Acinetobacter baumannii, in China.

                          Product Name : BV100

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 09, 2024

                          Lead Product(s) : Rifabutin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : GIBF2

                          Deal Size : $6.0 million

                          Deal Type : Financing

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Proceeds will enable the clinical development of BioVersys’ portfolio, including BV100 (rifabutin), a breakthrough antibiotic targeting Acinetobacter baumannii, a highly resistant bacterial pathogen.

                          Product Name : BV100

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 05, 2024

                          Lead Product(s) : Rifabutin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : GSK

                          Deal Size : $49.5 million

                          Deal Type : Series C Financing

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : BioVersys' lead candidate, BV100 (rifabutin), is being developed for lung and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB).

                          Product Name : BV100

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 01, 2023

                          Lead Product(s) : Rifabutin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : AMR Action Fund

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : BV100 is a much-needed injectable formulation of rifabutin to treat serious infections caused by Carbapenem Resistant Acinetobacter baumannii in patients with ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia and bloodstrea...

                          Product Name : BV100

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 25, 2022

                          Lead Product(s) : Rifabutin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : BioVersys AG

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : BioVersys has developed a proprietary human IV formulation of BV100 for the CRAB hospital market and elucidated the unique mode of action that accounts for its tremendous potency and coverage of clinical CRAB isolates.

                          Product Name : BV100

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 18, 2020

                          Lead Product(s) : Rifabutin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank